Tags

Type your tag names separated by a space and hit enter

Necrobiotic xanthogranuloma.
Dermatol Online J 2012; 18(12):30DO

Abstract

Necrobiotic xanthogranuloma (NXG) is a rare, chronic, progressive, non-Langerhans histiocytosis that is strongly associated with hematologic malignant conditions. Only about 100 cases have been reported in the literature since it was first described in 1980. It is important for dermatologists to recognize NXG and initiate a prompt hematologic evaluation. IgG kappa is the most frequently discovered monoclonal gammopathy (65%), followed by IgG lambda (35%), and, much less commonly, IgA. Although no modality has been shown to be consistently effective, therapeutic options include glucocorticoids (topical, intralesional, and/or systemic), alkylating agents (chlorambucil and cyclophosphamide). interferon alpha, antimetabolites, antibiotics, thalidomide, and plasmaphersis.

Authors+Show Affiliations

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

23286820

Citation

Rose, Amy, et al. "Necrobiotic Xanthogranuloma." Dermatology Online Journal, vol. 18, no. 12, 2012, p. 30.
Rose A, Robinson M, Kamino H, et al. Necrobiotic xanthogranuloma. Dermatol Online J. 2012;18(12):30.
Rose, A., Robinson, M., Kamino, H., & Latkowski, J. A. (2012). Necrobiotic xanthogranuloma. Dermatology Online Journal, 18(12), p. 30.
Rose A, et al. Necrobiotic Xanthogranuloma. Dermatol Online J. 2012 Dec 15;18(12):30. PubMed PMID: 23286820.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Necrobiotic xanthogranuloma. AU - Rose,Amy, AU - Robinson,Maria, AU - Kamino,Hideko, AU - Latkowski,Jo-Ann, Y1 - 2012/12/15/ PY - 2013/1/5/entrez PY - 2013/1/5/pubmed PY - 2013/6/19/medline SP - 30 EP - 30 JF - Dermatology online journal JO - Dermatol. Online J. VL - 18 IS - 12 N2 - Necrobiotic xanthogranuloma (NXG) is a rare, chronic, progressive, non-Langerhans histiocytosis that is strongly associated with hematologic malignant conditions. Only about 100 cases have been reported in the literature since it was first described in 1980. It is important for dermatologists to recognize NXG and initiate a prompt hematologic evaluation. IgG kappa is the most frequently discovered monoclonal gammopathy (65%), followed by IgG lambda (35%), and, much less commonly, IgA. Although no modality has been shown to be consistently effective, therapeutic options include glucocorticoids (topical, intralesional, and/or systemic), alkylating agents (chlorambucil and cyclophosphamide). interferon alpha, antimetabolites, antibiotics, thalidomide, and plasmaphersis. SN - 1087-2108 UR - https://www.unboundmedicine.com/medline/citation/23286820/Necrobiotic_xanthogranuloma_ L2 - http://www.diseaseinfosearch.org/result/7560 DB - PRIME DP - Unbound Medicine ER -